Edition:
United States

Resverlogix Corp (RVX.TO)

RVX.TO on Toronto Stock Exchange

1.30CAD
11:56am EDT
Change (% chg)

$-0.01 (-0.76%)
Prev Close
$1.31
Open
$1.34
Day's High
$1.34
Day's Low
$1.30
Volume
4,600
Avg. Vol
59,377
52-wk High
$2.47
52-wk Low
$1.12

Latest Key Developments (Source: Significant Developments)

Resverlogix randomizes first patient in Taiwan portion of Betonmace clinical trial
Monday, 10 Jul 2017 07:00am EDT 

July 10 (Reuters) - Resverlogix Corp :Resverlogix randomizes first patient in Taiwan/China portion of the phase 3 Betonmace clinical trial.As a result of randomization hepalink is now responsible for first c$1 million payment to Resverlogix.Co to be eligible to sales-based milestone payments from Hepalink when Apabetalone reaches annual sales milestones in territories.Each sales-based milestone ranging from $5 million to $90 million.  Full Article

Resverlogix announces fourth positive recommendation from DSMB
Wednesday, 28 Jun 2017 07:00am EDT 

June 28 (Reuters) - Resverlogix Corp :Resverlogix announces fourth positive recommendation from data safety monitoring board for phase 3 study of apabetalone.Says ‍dsmb reviewed available study data and noted that no safety or efficacy concerns were identified​.Resverlogix corp - recommendation confirms that apabetalone continues to be safe and well-tolerated.Says ‍will conduct additional periodic reviews​.Says ‍resverlogix, clinical steering committee, and all investigators remain blinded to trial data​.Resverlogix corp - remain on track for full enrollment by fall of 2017.  Full Article

Eastern Capital Ltd acquires additional shares and warrants of Resverlogix Corp
Tuesday, 20 Jun 2017 06:34pm EDT 

June 20 (Reuters) - Resverlogix Corp -:Eastern Capital Limited acquires additional shares and warrants of Resverlogix Corp.Eastern Capital Limited has acquired 1.6 million units issued by Resverlogix Corp at a price of c$1.80 per unit.  Full Article

Resverlogix closed offering, issuing a total of $10 million of equity units
Tuesday, 20 Jun 2017 09:34am EDT 

June 20 (Reuters) - Resverlogix Corp :Closed its previously-announced offering, issuing a total of $10 million of its equity units.  Full Article

Resverlogix announces overnight marketed equity offering
Thursday, 8 Jun 2017 04:01pm EDT 

June 8 (Reuters) - Resverlogix Corp :Resverlogix announces overnight marketed equity offering.Will undertake an overnight marketed offering of units, comprised of common shares and common share purchase warrants.  Full Article

Resverlogix wins Health Canada nod to test Fabry disease drug
Tuesday, 30 May 2017 07:00am EDT 

May 30 (Reuters) - Resverlogix Corp :Resverlogix receives approval from health canada to proceed with fabry disease clinical trial with lead compound apabetalone.Resverlogix- received approval from health canada, therapeutic products directorate, to proceed with clinical trial with lead compound apabetalone in patients with fabry disease.  Full Article

Resverlogix says proposed Phase 2A kidney dialysis study design to be separated in two parts
Thursday, 23 Feb 2017 07:00am EST 

Resverlogix Corp : Resverlogix - study to evaluate if treatment with apabetalone with standard of care decreases alkaline phosphatase in comparison to placebo and soc . Resverlogix reports positive FDA type B meeting on design issues relating to a proposed phase 2A kidney dialysis trial . Resverlogix Corp - in light of guidance received from FDA, phase 2A study design will be separated in two parts . Resverlogix Corp - part a of study will involve a single-dose pharmacokinetic (PK) study in eight patients receiving hemodialysis . Resverlogix Corp - PK results from part a will influence dose selection for part B study . Resverlogix Corp - part B study will be a double-blind, randomized, placebo-controlled, sequential cross-over study with apabetalone .Resverlogix Corp - intends to file an official investigative new drug (IND) application and proceed with planned phase 2A clinical trial in 2017.  Full Article

Resverlogix announces positive recommendation from data safety monitoring board for Apabetalone phase 3 study
Thursday, 11 Aug 2016 07:00am EDT 

Resverlogix Corp : Resverlogix announces positive recommendation from data safety monitoring board for phase 3 study of Apabetalone (rvx-208) . Data review by independent data safety monitoring board resulted in verbal recommendation for Betonmace trial to continue as planned .Dsmb reviewed available study data and noted that no safety or efficacy concerns were identified.  Full Article

Resverlogix explores potential of Apabetalone in phase 3 Betonmace clinical study
Tuesday, 24 May 2016 08:18pm EDT 

Resverlogix Corp : Potential of Apabetalone for treatment of high-risk diabetes and CKD is being explored in co's phase 3 Betonmace clinical study .Says no increase in infections was reported in phase 2 trials.  Full Article

BRIEF-Resverlogix randomizes first patient in Taiwan portion of Betonmace clinical trial

* Resverlogix randomizes first patient in Taiwan/China portion of the phase 3 Betonmace clinical trial